Pfizer files for U.S. authorization of promising COVID-19 antiviral pill
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Pfizer (PFE) Announces Agreement to Supply 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to US Govt
November 18, 2021 6:45 AM ESTPfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). If approved or authorized, PAXLOVID, which originated in Pfizers... More
Pfizer (PFE) Announces CFO Retirement
November 17, 2021 6:46 AM ESTPfizer Inc. (NYSE: PFE) today announced that Frank DAmelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year distinguished career with the Company. Pfizer has initiated an external search for a new Chief Financial Officer and DAmelio has agreed to stay on board through this process and serve in a consulting role through the transition. With DAmelios planned departure, and his significant contributions to Pfizers manufacturing capabilities, the Company has made the decision to name Mike McDermott, Executive... More
